Search results for "time factor"

showing 10 items of 3219 documents

Changes in ochratoxin A and type B trichothecenes contained in wheat flour during dough fermentation and bread baking processes

2009

Ochratoxin A (OTA) and type B trichothecenes are mycotoxins that occur frequently in cereals and thus can be found in cereal by-products such as bread. The aim of this work was to study the variation of the levels of OTA, deoxynivalenol (DON), 3-acetyldeoxynivalenol (3-ADON) and nivalenol (NIV) during the bread-making process. This was done by using wheat flour spiked with different levels of toxins. Mycotoxin levels were controlled after fermentation of the dough with yeasts (Saccharomyces cerevisiae) and after further baking at different temperature-time combinations. Analysis of variance (ANOVA) of the results showed a significant reduction in OTA level (p < 0.05) during fermentation of …

Ochratoxin ATime FactorsFood HandlingHealth Toxicology and MutagenesisTrichotheceneFlourWheat flourToxicology01 natural scienceschemistry.chemical_compound0404 agricultural biotechnologyVomitoxinFood scienceMycotoxinOchratoxin2. Zero hungerChemistry010401 analytical chemistryPublic Health Environmental and Occupational HealthTemperaturefood and beveragesLife Sciences04 agricultural and veterinary sciencesGeneral ChemistryGeneral MedicineBreadMycotoxins040401 food scienceOchratoxins0104 chemical sciencesFermentationFermentationEdible GrainTrichothecenesFood ScienceFood contaminantChromatography Liquid
researchProduct

Effect of carbendazim and physicochemical factors on the growth and ochratoxin A production of Aspergillus carbonarius isolated from grapes.

2007

Carbendazim is a systemic fungicide that is commonly used on several crops (tobacco, fruit, vegetables, cereals, etc.). This fungicide is used to control fungal infections in vineyards. It is indicated against Botrytis cinerea, Uncinula necator, Plasmopara viticola and other fungi and can be used either alone or coupled with other fungicides. However, there is a lack of in-depth studies to evaluate its effectiveness against growth of Aspergillus carbonarius isolated from grapes and OTA production. A medium based on red grape juice was used in this study. Preliminary studies were performed at 0.98 a(w) and 25 degrees C using carbendazim concentrations over a wide range (1-2000 ng/ml medium) …

Ochratoxin ATime FactorsMicrobiologyModels Biologicalchemistry.chemical_compoundBotanyVitisFood scienceMycotoxinOchratoxinBotrytis cinereaUncinula necatorAnalysis of VariancebiologyDose-Response Relationship DrugCarbendazimTemperaturefood and beveragesWaterGeneral Medicinebiology.organism_classificationOchratoxinsFungicides IndustrialFungicideKineticsAspergilluschemistryPlasmopara viticolaFood MicrobiologyBenzimidazolesCarbamatesFood ScienceInternational journal of food microbiology
researchProduct

Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardi…

2014

Data on the long-term metabolic side-effects associated with antipsychotics are scarce. Prospective longitudinal studies in medication-naive patients with a first episode of psychosis are a valuable source of information as they provide an assessment prior to the antipsychotic exposure and minimize the effect of potential confounding factors. The aim of this study was to assess the course of weight gain and the incidence of metabolic abnormalities during the first 3 yr of antipsychotic treatment. Data were collected from a cohort of 170 first-episode psychosis patients. They were randomly assigned to haloperidol (32%); olanzapine (32%) and risperidone (36%). The dose used was flexible. The …

OlanzapineAdultMaleMedication-naivemedicine.medical_specialtyTime FactorsAdolescentmedicine.medical_treatmentWeight GainBenzodiazepinesYoung AdultMetabolic DiseasesRisk FactorsMetabolic side effectsInternal medicinemedicineHumansAntipsychoticsPharmacology (medical)Prospective StudiesAntipsychoticPsychiatryProspective cohort studyPharmacologyFirst episodeRisperidoneMiddle AgedRisperidoneFirst-episode psychosisCardiovascular riskCritical periodPsychiatry and Mental healthTolerabilityPsychotic DisordersOlanzapineCohortHaloperidolmedicine.symptomPsychologyWeight gainmedicine.drugAntipsychotic Agents
researchProduct

Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.

2002

Olanzapine is a substrate of the cytochrome P450 enzyme (CYP) 1A2. In this study, pharmacokinetic interactions and clinical effects of adding the CYP1A2 inhibitor fluvoxamine to steady-state olanzapine was examined in patients suffering from schizophrenia. Eight patients had been treated for at least 3 months with 10 to 20 mg/day olanzapine. Fluvoxamine (100 mg/day) was added (week 0) to the olanzapine treatment and continued for 8 weeks. Concentrations of olanzapine and its metabolite N-desmethylolanzapine and of fluvoxamine were analyzed at weeks 0, 1, 4, and 8. Addition of fluvoxamine resulted in a 12% to 112% (0.01) increase of olanzapine from 31 +/- SD 15 ng/mL (week 0) to 56 +/- 31 ng…

OlanzapineAdultMaleTime FactorsCombination therapyFluvoxaminePharmacologyBenzodiazepinesPharmacokineticsmedicineHumansPharmacology (medical)Drug InteractionsProspective Studiesmedicine.diagnostic_testbusiness.industryDopamine antagonistPirenzepineDrug interactionMiddle AgedPsychiatry and Mental healthTherapeutic drug monitoringChemotherapy AdjuvantFluvoxamineOlanzapineChronic DiseaseSchizophreniaFemalebusinessReuptake inhibitorSelective Serotonin Reuptake Inhibitorsmedicine.drugFollow-Up StudiesJournal of clinical psychopharmacology
researchProduct

The GiSAS study: Rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatme…

2011

Given the controversy about the comparative efficacy of first- compared with second-generation antipsychotics in the treatment of schizophrenia, more large-scale evidence is needed to guide clinicians in their prescriptions. Most randomized controlled trials (RCTs) were conducted in centers of excellence on highly selected samples, poorly representative of real-world patients, and often suffered conflicts of interest as they were sponsored by drug companies. The primary aim of the present study is to compare the effectiveness of haloperidol, olanzapine and aripiprazole in a representative sample of schizophrenia patients. The GiSAS trial is an open-label, independent, pragmatic RCT in Itali…

Olanzapinemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAripiprazoleQuinolonesPragmatic trialPiperazineslaw.inventionAntipsychoticBenzodiazepinesRandomized controlled triallawAntipsychotic; Pragmatic trial; SchizophreniamedicineClinical endpointHumansPharmacology (medical)AntipsychoticPsychiatrySettore MED/25 - PsichiatriaProportional Hazards Modelsbusiness.industryPatient SelectionGeneral MedicineDiscontinuationLogistic ModelsItalyTolerabilityOlanzapineResearch DesignSchizophreniaPhysical therapyHaloperidolObservational studyAripiprazoleantipsychotic schizophrenia metabolic syndromebusinessAntipsychotic Agentsmedicine.drugContemporary Clinical Trials
researchProduct

Olfactory function after microscopic endonasal surgery in patients with nasal polyps.

1997

A controlled prospective study on 31 patients with nasal polyps was performed to evaluate the time course of olfactory function after endonasal surgery. A modified Connecticut Chemosensory Clinical Research Center (CCCRC) olfactory function test was used to measure olfactory threshold, odor identification ability, and odor discrimination ability. The test was performed in all patients 1–3 days before surgery (V1), 7–10 days after surgery (V2), and after 1 (V3), 2 (V4), 3 (V5), and 6 (V6) months. Mean olfactory threshold in the CCCRC butanol test was 4.19 at V1 (= moderate hyposmia). At V2, it decreased to 3.46 (= severe hyposmia), before increasing to 5.16 at V3 and 5.22 at V4 (= mild hypo…

Olfactory systemAdultMalemedicine.medical_specialtyTime Factors03 medical and health sciences0302 clinical medicineNasal PolypsmedicineHumansIn patientNasal polypsProspective Studies030223 otorhinolaryngologyProspective cohort studyPostoperative Carebusiness.industryEndoscopyOlfactory PathwaysMiddle Agedmedicine.diseaseSurgerySmellOtorhinolaryngology030220 oncology & carcinogenesisTime courseFemalebusinessAmerican journal of rhinology
researchProduct

Synaptogenesis in the mouse olfactory bulb during glomerulus development

2008

Synaptogenesis is essential for the development of neuronal networks in the brain. In the olfactory bulb (OB) glomeruli, numerous synapses must form between sensory olfactory neurons and the dendrites of mitral/tufted and periglomerular cells. Glomeruli develop from E13 to E16 in the mouse, coincident with an increment of the neuropil in the border between the external plexiform (EPL) and olfactory nerve layers (ONL), coupled to an extensive labelling of phalloidin and GAP-43 from the ONL to EPL. We have tracked synaptogenesis in the OB during this period by electron microscopy (EM) and immunolabelling of the transmembrane synaptic vesicle glycoprotein SV-2. No SV-2 labelling or synapses we…

Olfactory systemNeuropilTime FactorsPhalloidineSynaptic MembranesSynaptogenesisGAP-43Nerve Tissue ProteinsBiologymitral cellsSynaptic TransmissionOlfactory Receptor NeuronsMiceGAP-43 ProteinOlfactory MucosaOlfactory nerveolfactory sensory neuronsNeuropilmedicineAnimalsGlomerulus (olfaction)Membrane GlycoproteinsGeneral NeuroscienceSV-2Cell DifferentiationDendritesOlfactory BulbOlfactory bulbmedicine.anatomical_structureSynapsesembryonic structuresSynaptic VesiclesOlfactory ensheathing gliaolfactory epitheliumsense organsNeuroscienceOlfactory epitheliumBiomarkers
researchProduct

Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (pCR) after primary chemotherapy.

2009

Abstract Learning Objectives After completing this course, the reader will be able to: Summarize the main risk factors for relapse in patients with T4 breast cancer after neoadjuvant chemotherapy.Evaluate the role of hormone receptors and HER-2 as determinants of risk of relapse after neoadjuvant treatment.Compare the difference in outcomes between patients who achieve less than pCR in relation to receptor status. This article is available for continuing medical education credit at CME.TheOncologist.com. Purpose. Pathological complete response (pCR) to primary chemotherapy is the main determinant for improved disease-free survival (DFS) and overall survival (OS). The primary endpoints of ou…

OncologyAdultCancer Researchmedicine.medical_specialtyTime FactorsSettore MED/06 - Oncologia MedicaReceptor ErbB-2Breast NeoplasmsVinorelbineDisease-Free SurvivalBreast cancerTrastuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPathologicalMastectomyAgedNeoplasm StagingCisplatinStage IIIB breast cancerNeoadjuvant chemotherapyPathological responseLong-term outcomesbusiness.industryRadiotherapy DosageMiddle Agedmedicine.diseasePrognosisCombined Modality TherapySurvival RateRegimenTreatment OutcomeOncologyHormone receptorLymphatic MetastasisFemaleLymph Nodesbusinessmedicine.drugEpirubicinFollow-Up StudiesThe oncologist
researchProduct

Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy.

1990

Abstract purpose: A phase Ib/II clinical study was undertaken to assess the efficacy of recombinant human (rh) granulocyte-macrophage colony-stimulating (GM-CSF) factor in attenuating neutropenia and associated morbidity caused by high-dose anticancer chemotherapy administered in the presence or absence of autologous bone marrow support. patients and methods: Twenty-two patients with various solid tumors and lymphoid neoplasias were treated with a single daily subcutaneous dose of rh GM-CSF (250/μg/m 2 ) 48 hours after receiving a second cycle of highly myelotoxic chemotherapy for a period of 10 days. Within-subject comparisons on neutropenia-related clinical and laboratory variables were m…

OncologyAdultMalemedicine.medical_specialtyNeutropeniaTime FactorsAdolescentmedicine.drug_classNeutrophilsmedicine.medical_treatmentAntibioticsNeutropeniaLeukocyte CountColony-Stimulating FactorsBone MarrowInternal medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIn patientGrowth SubstancesAgedBone Marrow TransplantationChemotherapybusiness.industryCancerGranulocyte-Macrophage Colony-Stimulating FactorGeneral MedicineMiddle AgedAutologous bonemedicine.diseaseRecombinant ProteinsAnti-Bacterial AgentsGranulocyte macrophage colony-stimulating factorImmunologyToxicityDrug EvaluationFemalebusinessmedicine.drugAgranulocytosisThe American journal of medicine
researchProduct

Hepatocellular carcinoma: comparison of two different periods at the same center.

2010

Aims: To analyze the main etiological factors and some clinical characteristics of patients with HCC at diagnosis and to compare them with those we described ten years ago. Methods: 179 patients were included in Group 1, while 132 patients were included in Group 2. For all patients age, sex, serum markers of hepatitis B and C viruses, alcohol consumption, serum alpha feto-protein (AFP) levels and the main liver function parameters at HCC diagnosis were recorded. Results: Mean age was 66.0 years for Group 1 and 69.0 for Group 2 (P=0.005). HCV was responsible for 80.3% of HCC cases in Group 2 versus 72% in Group 1 (P=0.005). HBV alone and co-infection of HCV+HBV decreased, but not significant…

OncologyAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaCarcinoma HepatocellularTime FactorsAlcohol DrinkingAlpha (ethology)Gastroenterologyhepatocellular carcinoma Etiology Staging DiagnosisLiver diseaseLiver Function TestsInternal medicineInternal MedicinemedicineHumansAgedNeoplasm StagingAged 80 and overmedicine.diagnostic_testbusiness.industryLiver NeoplasmsHepatitis CHepatitis BMiddle Agedmedicine.diseaseHepatitis BHepatitis Cdigestive system diseasesItalyHepatocellular carcinomaEtiologyFemaleLiver functionalpha-FetoproteinsLiver function testsbusinessEuropean journal of internal medicine
researchProduct